Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
Patients with recurrent superficial bladder tumors have been treated by vesical and intradermal administration of Bacillus Calmette-Guerin. The pattern of recurrence in 9 patients has been altered favorably. Although the findings are still preliminary they appear to hold promise of a new therapeutic approach to the treatment of a group of neoplasms for which effective therapy is still lacking.
D000368:Aged; D001500:BCG Vaccine; D002295:Carcinoma, Transitional Cell / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed; D007167:Immunotherapy; D007958:Leukocyte Count; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009163:Mycobacterium bovis / Q000276:immunology*; D009364:Neoplasm Recurrence, Local; D013852:Thiotepa / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000628:therapy*
D001500:BCG Vaccine; D013852:Thiotepa